Business Context and Reporting Period
This Form 8-K reports on the 2022 Annual Meeting of Stockholders held by Black Diamond Therapeutics, Inc. on June 7, 2022. The meeting was conducted in a virtual-only format via live webcast. As of the record date of April 13, 2022, there were 36,287,568 shares of Common Stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and voting results.
Material Changes and Voting Results
Stockholders voted on two primary proposals. A quorum was established with 30,154,709 shares present or represented by valid proxy.
Proposal No. 1: Election of Class II Directors
Three nominees were elected to the Board of Directors to serve until the 2025 annual meeting. The voting results were as follows:
| Nominee | For | Withheld | Broker Non-Votes |
|---|---|---|---|
| Ali Behbahani, M.D. | 18,224,883 | 8,966,028 | 2,963,798 |
| Garry E. Menzel, Ph.D. | 18,573,133 | 8,617,778 | 2,963,798 |
| Samarth Kulkarni, Ph.D. | 21,847,776 | 5,343,135 | 2,963,798 |
Proposal No. 2: Ratification of Independent Auditor
Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2022.
| Vote Type | Count |
|---|---|
| For | 30,085,952 |
| Against | 13,975 |
| Abstain | 54,782 |
| Broker Non-Votes | 0 |
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the reporting of voting outcomes.
Key Facts for Investor Verification
- Meeting Date: June 7, 2022.
- Quorum Status: Established with 30,154,709 shares present (83.1% of outstanding shares).
- Board Composition: Ali Behbahani, Garry E. Menzel, and Samarth Kulkarni were elected as Class II directors.
- Auditor: PricewaterhouseCoopers LLP was ratified for the 2022 fiscal year.
- Financial Data: No financial performance metrics are included in this specific filing; refer to the Proxy Statement filed on April 28, 2022, or the most recent 10-K/10-Q for financial details.